BioAge Labs, Inc.
BIOA•NASDAQ•Healthcare•Drug Manufacturers - Specialty & Generic

About BioAge Labs

BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitebioagelabs.com
Phone510 806 1445
Address
1445A South 50th Street Richmond, California 94804 United States

Corporate Identifiers

CIK0001709941
CUSIP09077V100
ISINUS09077V1008
EIN47-4721157
SIC2834

Leadership Team & Key Executives

Dr. Kristen Fortney Ph.D.
Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director
Dr. Eric Morgen M.D.
Co-Founder, Chief Operating Officer and Director
Dr. Paul D. Rubin M.D.
Chief Medical Officer and Executive Vice President of Research
Dr. Dov A. Goldstein M.B.A., M.D.
Chief Financial Officer
Rusty Montgomery Ph.D.
Senior Vice President of Research
Julie Gammelgard
Senior Vice President of People
Dr. Peng Leong M.B.A., Ph.D.
Chief Business Officer and Therapeutic Area Head of Brain Aging
BJ Sullivan Ph.D.
Chief Strategy Officer
Ann C. Neale RN BSN
Chief Development Officer
Patrick Martin M.D.
Senior Vice President of Clinical Science